OppenheimerFunds’s GSK GSK Stock Holding History

OppenheimerFunds’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$21.8M	Buy	417,512 +23,578	+6%	+$1.18M	0.03%	511
2018 Q4	$18.8M	Buy	393,934 +60,088	+18%	+$2.96M	0.03%	531
2018 Q3	$16.8M	Buy	+333,846	New	+$17M	0.02%	627
2017 Q4	–	Sell	-703,466	Closed	-$35.7M	–	1855
2017 Q3	$35.7M	Buy	703,466 +187,398	+36%	+$9.51M	0.04%	389
2017 Q2	$27.8M	Buy	516,068 +120,869	+31%	+$6.44M	0.03%	450
2017 Q1	$20.8M	Buy	395,199 +315,965	+399%	+$16M	0.03%	568
2016 Q4	$3.81M	Buy	79,234 +20,380	+35%	+$1.01M	﹤0.01%	856
2016 Q3	$3.17M	Sell	58,854 -12	-0%	-$658	﹤0.01%	855
2016 Q2	$3.19M	Buy	58,866 +16,521	+39%	+$870K	﹤0.01%	838
2016 Q1	$2.15M	Sell	42,345 -473,943	-92%	-$23.6M	﹤0.01%	882
2015 Q4	$26M	Sell	516,288 -606,152	-54%	-$30.9M	0.03%	491
2015 Q3	$27M	Buy	1,122,440 +284,608	+34%	+$14.8M	0.04%	460
2015 Q2	$43.6M	Sell	837,832 -30,084	-3%	-$1.69M	0.05%	384
2015 Q1	$50.1M	Buy	867,916 +25,644	+3%	+$1.47M	0.06%	374
2014 Q4	$45M	Buy	842,272 +275,244	+49%	+$15.4M	0.05%	378
2014 Q3	$32.6M	Buy	567,028 +26,008	+5%	+$1.59M	0.04%	451
2014 Q2	$36.2M	Buy	541,020 +20,020	+4%	+$1.36M	0.04%	427
2014 Q1	$34.8M	Buy	521,000 +16,040	+3%	+$1.08M	0.04%	429
2013 Q4	$33.7M	Buy	504,960 +68,580	+16%	+$4.45M	0.04%	436
2013 Q3	$27.4M	Buy	436,380 +380	+0.1%	+$24.5K	0.04%	461
2013 Q2	$27.2M	Buy	+436,000	New	+$27.7M	0.04%	453

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

OppenheimerFunds's GSK Position: Q1 2019 in Review

OppenheimerFunds increased its GSK (GSK) stake by 6% in Q1 2019, buying an estimated $1.18M and bringing the position to 417,512 shares worth $21.8M. The position accounts for 0.03% of the portfolio, ranked #511.

OppenheimerFunds first reported a position in GSK in Q2 2013 and has held it in 21 quarters since. The position peaked at $50.1M in Q1 2015. 847 funds tracked by Wall St. Rank hold GSK as of Q1 2019.

OppenheimerFunds held 417,512 shares of GSK worth $21.8M as of Q1 2019.
OppenheimerFunds bought 23,578 GSK shares in Q1 2019, an estimated $1.18M.
GSK made up 0.03% of OppenheimerFunds's portfolio in Q1 2019, its #511 holding.
OppenheimerFunds first reported a position in GSK in Q2 2013 and has held it in 21 quarters since.
OppenheimerFunds's GSK position peaked at $50.1M in Q1 2015.
847 funds tracked by Wall St. Rank held GSK as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.